KRAS Mutation Analysis: a Comparison Between Primary Tumours and Matched Liver Metastases in 305 Colorectal Cancer Patients

Overview

Journal Br J Cancer

Specialty Oncology

Date 2011 Mar 3

PMID 21364579

Citations 137

Authors

N Knijn

L J M Mekenkamp

M Klomp

M E Vink-Borger

J Tol

S Teerenstra

J W R Meijer

M Tebar

S Riemersma

J H J M van Krieken

C J A Punt

I D Nagtegaal

Affiliations

Soon will be listed here.

Abstract

Background: KRAS mutation is a negative predictive factor for treatment with anti-epidermal growth factor receptor antibody in metastatic colorectal cancer (CRC). KRAS mutation analysis is usually performed on primary tumour tissue because metastatic tissue is often not available. However, controversial data are available on the concordance of test results between primary tumours and corresponding metastases. We assessed the concordance of KRAS mutation status in a study of 305 primary colorectal tumours and their corresponding liver metastases.

Methods: Patients with histologically confirmed CRC who underwent surgical resection of the primary tumour and biopsy or surgical resection of the corresponding liver metastasis were included. KRAS mutation analysis was performed for codons 12 and 13.

Results: KRAS mutation was detected in 108 out of 305 primary tumours (35.4%). In 11 cases (3.6%), we found a discordance between primary tumour and metastasis: 5 primary tumours had a KRAS mutation with a wild-type metastasis, 1 primary tumour was wild type with a KRAS mutation in the metastasis, and in 5 cases the primary tumour and the metastasis had a different KRAS mutation.

Conclusion: We observed a high concordance of KRAS mutation status of 96.4% (95% CI 93.6-98.2%) between primary colorectal tumours and their corresponding liver metastases. In only six patients (2.0%; 95% CI 0.7-4.2%), the discordance was clinically relevant. In this largest and most homogenous study to date, we conclude that both primary tumours and liver metastases can be used for KRAS mutation analysis.

Citing Articles

The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives.

Takeda M, Yoshida S, Inoue T, Sekido Y, Hata T, Hamabe A Cancers (Basel). 2025; 17(3).

PMID: 39941797 PMC: 11816235. DOI: 10.3390/cancers17030428.

Use of a Pathomics Nomogram to Predict Postoperative Liver Metastasis in Patients with Stage III Colorectal Cancer.

Zheng J, Wang T, Wang H, Yan B, Lai J, Qiu K Ann Surg Oncol. 2024; 32(2):771-782.

PMID: 39614006 DOI: 10.1245/s10434-024-16519-8.

Dynamics of RAS Mutations in Liquid Biopsies in Metastatic Colorectal Cancer Patients-Case Series and Literature Review.

Popescu I, Croitoru V, Croitoru-Cazacu I, Dudau A, Herlea V, Dima S J Pers Med. 2024; 14(7).

PMID: 39064004 PMC: 11278408. DOI: 10.3390/jpm14070750.

Multilevel Heterogeneity of Colorectal Cancer Liver Metastasis.

Chen H, Zhai C, Xu X, Wang H, Han W, Shen J Cancers (Basel). 2024; 16(1).

PMID: 38201487 PMC: 10778489. DOI: 10.3390/cancers16010059.

Neo-Antigen-Reactive T Cells Immunotherapy for Colorectal Cancer: A More Personalized Cancer Therapy Approach.

Chen G, Kong D, Lin Y Glob Chall. 2023; 7(11):2200186.

PMID: 37970536 PMC: 10632666. DOI: 10.1002/gch2.202200186.

References

Zauber P, Sabbath-Solitare M, Marotta S, Bishop D . Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas. Mol Pathol. 2003; 56(3):137-40. PMC: 1187308. DOI: 10.1136/mp.56.3.137. View

Oliveira C, Velho S, Moutinho C, Ferreira A, Preto A, Domingo E . KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene. 2006; 26(1):158-63. DOI: 10.1038/sj.onc.1209758. View

Klein C . Parallel progression of primary tumours and metastases. Nat Rev Cancer. 2009; 9(4):302-12. DOI: 10.1038/nrc2627. View

Cejas P, Lopez-Gomez M, Aguayo C, Madero R, de Castro Carpeno J, Belda-Iniesta C . KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PLoS One. 2009; 4(12):e8199. PMC: 2792724. DOI: 10.1371/journal.pone.0008199. View

Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D . PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol. 2009; 27(16):2622-9. DOI: 10.1200/JCO.2008.20.2796. View

Santini D, Loupakis F, Vincenzi B, Floriani I, Stasi I, Canestrari E . High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist. 2008; 13(12):1270-5. DOI: 10.1634/theoncologist.2008-0181. View

Suchy B, Zietz C, Rabes H . K-ras point mutations in human colorectal carcinomas: relation to aneuploidy and metastasis. Int J Cancer. 1992; 52(1):30-3. DOI: 10.1002/ijc.2910520107. View

Oliveira C, Westra J, Arango D, Ollikainen M, Domingo E, Ferreira A . Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet. 2004; 13(19):2303-11. DOI: 10.1093/hmg/ddh238. View

Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S . Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007; 67(6):2643-8. DOI: 10.1158/0008-5472.CAN-06-4158. View

10.

Van Cutsem E, Kohne C, Hitre E, Zaluski J, Chang Chien C, Makhson A . Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360(14):1408-17. DOI: 10.1056/NEJMoa0805019. View

11.

Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, Filipits M . EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res. 2009; 15(14):4554-60. DOI: 10.1158/1078-0432.CCR-09-0089. View

12.

De Roock W, Jonker D, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S . Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010; 304(16):1812-20. DOI: 10.1001/jama.2010.1535. View

13.

Garm Spindler K, Pallisgaard N, Rasmussen A, Lindebjerg J, Andersen R, Cruger D . The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Ann Oncol. 2009; 20(5):879-84. DOI: 10.1093/annonc/mdn712. View

14.

Weber J, Meyer N, Pencreach E, Schneider A, Guerin E, Neuville A . Allelotyping analyses of synchronous primary and metastasis CIN colon cancers identified different subtypes. Int J Cancer. 2006; 120(3):524-32. DOI: 10.1002/ijc.22343. View

15.

Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M . PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol. 2008; 20(1):84-90. DOI: 10.1093/annonc/mdn541. View

16.

Tol J, Koopman M, Cats A, Rodenburg C, Creemers G, Schrama J . Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009; 360(6):563-72. DOI: 10.1056/NEJMoa0808268. View

17.

Al-Mulla F, Going J, Sowden E, Winter A, Pickford I, BIRNIE G . Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality. J Pathol. 1998; 185(2):130-8. DOI: 10.1002/(SICI)1096-9896(199806)185:2<130::AID-PATH85>3.0.CO;2-M. View

18.

Etienne-Grimaldi M, Formento J, Francoual M, Francois E, Formento P, Renee N . K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res. 2008; 14(15):4830-5. DOI: 10.1158/1078-0432.CCR-07-4906. View

19.

Artale S, Sartore-Bianchi A, Veronese S, Gambi V, Sarnataro C, Gambacorta M . Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol. 2008; 26(25):4217-9. DOI: 10.1200/JCO.2008.18.7286. View

20.

Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P . Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008; 26(35):5705-12. DOI: 10.1200/JCO.2008.18.0786. View